BioCentury
ARTICLE | Company News

Spring Bank and Gilead combo trial to treat chronic HBV

July 21, 2017 6:45 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) will fund and conduct a Phase II evaluating its HBV drug Vemlidy tenofovir alafenamide fumarate plus SB 9200 from Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) in patients with chronic HBV infection. Spring Bank said the trial is expected to begin 1Q18.

SB 9200 is a small molecule nucleic acid hybrid targeting DEAD box polypeptide 58 (RIG-I; DDX58) and caspase recruitment domain family member 15 (CARD15; NOD2). In May, Spring Bank said top-line data from the lowest dose cohort of a Phase IIa study showed that SB 9200 met one of the trial's primary endpoints to treat chronic HBV infection. The company expects data in 4Q17 from a cohort evaluating a higher dose. ...